Navigation Links
Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication
Date:5/2/2012

LONDON, May 3, 2012 /PRNewswire/ --

Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, notes that its partner, Quark Pharmaceuticals, has announced it has amended its existing exclusive Licensing Agreement with Pfizer. This amendment will enable Quark to perform a Phase 2a clinical study to assess the effect of PF-655 in a new indication, looking at visual function in patients with moderate and advanced Open-Angle Glaucoma (OAG). PF-655 incorporates Silence's AtuRNAi technology and was sub-licensed to Pfizer by Quark in 2006, and on which Silence is entitled to receive a share of milestones and royalties that may be earned by Quark in the future on this compound.

The OAG study will be conducted in parallel with a Phase 2b study of PF-655 in diabetic macular oedema.

Silence has previously announced that it stood to receive up to $95m from Quark in relation to its licensing agreement with Pfizer. As a result of this amendment to the Quark/Pfizer license, Silence anticipates its share of these payments could now reach $120m. Silence has previously announced the receipt of $6m from Quark in relation to this licence.

Commenting on the announcement, Tony Sedgwick, Chief Executive Officer of Silence, said: "This is an exciting development for Silence. This will create a fifth external clinical program using Silence's IP and AtuRNAi, which is funded and managed by one of our partners. This will increase the potential share of milestones and royalties that Silence can earn under its agreement with Quark and is a further validation of th
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
2. Silence Therapeutics Additional Listing
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Silence Therapeutics Provides Corporate and Development Update
6. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
7. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... Cannavoices , Inc., a premier legal ... and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to become not ... stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, Investors, Ancillary ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... CAGR of around 19% during the forecast period (2015 to 2020). The market ... upsurge in government and corporate funding for R&D. However, lack of adequate healthcare ...
(Date:6/29/2015)... , June 29, 2015  Neuralstem, Inc. (NYSE ... technology to develop small molecule and cell therapy treatments ... has been approved for listing on the NASDAQ Capital ... will continue to trade on the NYSE MKT until ... the NASDAQ Capital Market is expected to commence on ...
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... Calif., July 9 Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced the appointment of Gary A. Lyons, to the ... of directors on the Poniard board to ten. , ... help guide us as we move toward our goal of ...
... , ROCKVILLE, Md., July 9 Human Genome ... by The New England Journal of Medicine ... which showed the life-saving potential of the Company,s human monoclonal ... human safety studies, which supported the use of raxibacumab in ...
... June 25, 2009 Veritide Ltd., a developer ... that new independent data to be presented at the ... its Ceeker (pronounced "seeker") portable bacterial detection device in ... The data show that in over two weeks of ...
Cached Biology Technology:Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 2Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 3Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 3Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 4Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 5Novel handheld device detects anthrax with outstanding accuracy and reliability 2Novel handheld device detects anthrax with outstanding accuracy and reliability 3
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
(Date:6/12/2015)... 2015  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announced the United ... capture, analyze and identify participants of a video ... This system can: , Identify ... subsequent sign-on process is actually the person participating ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... and growth. In order to identify new therapeutic targets ... clarify the mechanisms that control the expression of genes ... as uncontrolled cell division. Today, Nature has ... Mndez, ICREA professor at the Institute for Research in ...
... WOODS HOLE, Mass. Scientists at the Marine Biological Laboratory ... disorders, including Alzheimer,s disease, Parkinson,s disease and spinal cord ... whole-genome sequence is reported this week in the journal ... can use the sea lamprey as a powerful model ...
... known for turning on genes to help cells survive low-oxygen ... thus shutting down the growth of new cells, Johns Hopkins ... the importance of this copying known as DNA replication ... functions and in such diseases as cancer. , "We,ve ...
Cached Biology News:Researchers at IRB Barcelona discover a general mechanism that accelerates tumor development 2Researchers at IRB Barcelona discover a general mechanism that accelerates tumor development 3MBL scientists find genes linked to human neurological disorders in sea lamprey genome 2Flipping the 'off' switch on cell growth 2
...
... trays and universal trays make vessel ... Shaking speed: 40 - ... amplitude Clamps for Erlenmeyer ... including Fernbach flasks Hinged ...
... convenient, and efficient Denatured protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their Denatured condition. ... high binding capacity fo all pH values. ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
Biology Products: